Antisense oligonucleotides (ASOs) are being developed as treatments for rare genetic disorders such as SCN2A. What are they and how do they work? To help gain a better understanding of ASOs and their role we talk to Dr Stanley Crooke, founder of Ionis.

Hosted by Kris Pierce and David Cunnington, parents of Will, who has SCN2A.

Leave a review and subscribe via Apple Podcasts. 

You can also find SCN2A Insights on Spotify, and Google Podcasts or in your podcast app

Links

• American Epilepsy Society meeting
• Summary of ASO presentations at AES
• Dr Ana Mignorance - @CNSDrugHunter on Twitter
• Ionis 
• Webinar on ASO treatment for gain of function SCN2A

See omnystudio.com/listener for privacy information.